Zepp Health Reports Strong Q4 Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ZEPP?
Source: seekingalpha
- Earnings Highlights: Zepp Health reported a Q4 non-GAAP EPS loss of -$0.40, yet achieved revenue of $85.17 million, reflecting a robust 43% year-over-year growth, showcasing the company's resilience and growth potential in challenging times.
- Future Guidance: The company anticipates Q1 2026 revenue between $50 million and $55 million, representing a year-over-year increase of 30% to 43%, indicating ongoing improvements in execution and operational efficiency.
- Profitability Improvement: As Zepp Health enters a new phase of growth, the continuous enhancement in profitability underscores its strengthened competitive position, potentially positioning it as a household name in the market.
- Market Reaction: The unexpected turnaround of Zepp Health has garnered market attention, with Seeking Alpha's Quant Rating reflecting optimistic expectations for its future performance, further boosting investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZEPP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZEPP
Wall Street analysts forecast ZEPP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 20.590
Low
64.37
Averages
64.37
High
64.37
Current: 20.590
Low
64.37
Averages
64.37
High
64.37

No data
About ZEPP
Zepp Health Corp, formerly Huami Corp, is a Netherlands-based company primarily engaged in the consumer electronics and digital health technology industry. The Company focuses on developing smart wearable devices and digital health management platforms. Their key product is the Zepp Digital Health Management Platform, which is a cloud-based system integrating smart devices, biometric sensors, Artificial Intelligence (AI) chips, and data algorithms. It aims to provide users with 24/7 actionable insights to support health, fitness, and wellness management. The platform powers a range of products including smartwatches, fitness bands, smart rings, and hearables under the Amazfit and Zepp brand names. Additionally, the Company offers AI-driven services such as Zepp Aura for sound-based wellness and Zepp Clarity for hearing health. The Company has two reportable segments the Xiaomi wearable products segment and Self-branded products and others segment.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Significant Revenue Growth: Zepp Health reported total revenue of $258.9 million for 2025, reflecting a 41.8% year-over-year increase, driven by over 50% sales growth in Amazfit-branded products, indicating strong market performance in the wearable device sector.
- Record Gross Margin: The gross margin for Q4 2025 reached 40.4%, an increase of 3.6 percentage points compared to Q4 2024, showcasing the company's successful optimization of its product mix and ability to maintain pricing integrity during promotional periods, thereby enhancing profitability.
- Substantial Reduction in Net Loss: The net loss for 2025 was $40.1 million, significantly down from $75.7 million in 2024, indicating notable progress in cost control and operational efficiency, with expectations for continued financial improvement.
- Strong Cash Flow: As of December 31, 2025, the company had cash and cash equivalents of $112.9 million, an increase from $110.7 million in 2024, demonstrating robust operational performance and effective working capital management, providing ample resources for future investments.
See More
- Earnings Highlights: Zepp Health reported a Q4 non-GAAP EPS loss of -$0.40, yet achieved revenue of $85.17 million, reflecting a robust 43% year-over-year growth, showcasing the company's resilience and growth potential in challenging times.
- Future Guidance: The company anticipates Q1 2026 revenue between $50 million and $55 million, representing a year-over-year increase of 30% to 43%, indicating ongoing improvements in execution and operational efficiency.
- Profitability Improvement: As Zepp Health enters a new phase of growth, the continuous enhancement in profitability underscores its strengthened competitive position, potentially positioning it as a household name in the market.
- Market Reaction: The unexpected turnaround of Zepp Health has garnered market attention, with Seeking Alpha's Quant Rating reflecting optimistic expectations for its future performance, further boosting investor confidence.
See More
- Significant Revenue Growth: In 2025, Zepp Health achieved total revenues of $258.9 million, a 41.8% year-over-year increase, with Amazfit brand product sales growing by 50.9%, demonstrating the success of its brand transformation and enhancing market competitiveness.
- Record High Gross Margin: The gross margin for Q4 2025 reached 40.4%, up 3.6% from Q4 2024, primarily driven by product mix optimization and enhanced pricing power, with expectations for this trend to continue into 2026.
- Operating Expense Control: Although total operating expenses for Q4 were $38.3 million, an increase from the same period in 2024, the adjusted operating loss significantly decreased to $2.7 million due to effective cost control and revenue growth, indicating progress in financial management.
- Strong Cash Flow: As of December 31, 2025, Zepp Health's cash and cash equivalents stood at $112.9 million, an increase from $110.7 million in 2024, reflecting strong operational performance and tight working capital management, providing ample funding for future investments.
See More
- Earnings Report Announcement: Zepp Health is set to release its unaudited financial results for Q4 and full year 2025 on March 15, 2026, indicating the company's ongoing growth in the smart wearables and health technology sector.
- Conference Call Details: Management will hold a conference call at 9:30 p.m. ET, with participants required to dial in 10 minutes early, reflecting the company's commitment to investor communication and transparency.
- Global Market Reach: Zepp Health has shipped over 200 million units across more than 90 countries and regions, showcasing its significant influence and market penetration in the smart wearable and health technology markets.
- Brand Strategic Positioning: Since its founding in 2013, the company has rebranded from Huami Corp to Zepp Health, emphasizing its core focus on health technology and aiming to enhance brand value by optimizing users' health and fitness journeys.
See More
- Extreme Environment Design: The T-Rex Ultra 2 smartwatch from Amazfit is crafted with premium materials and enhanced navigation capabilities, featuring a 10 ATM water resistance rating, specifically designed to ensure reliability for athletes and explorers in complex routes.
- Outstanding Battery Life: This smartwatch boasts up to 30 days of battery life in smartwatch mode and over 50 hours of GPS tracking, supporting multi-day adventures, while users can save 64GB of maps and music directly on the device, enhancing outdoor activity convenience.
- Enhanced Navigation Features: For the first time in the T-Rex lineup, full-color global maps come preloaded, allowing users to quickly install necessary areas, supporting point-to-point route planning and offline navigation, significantly improving navigation capabilities in no-network environments.
- Smart Reminder System: The T-Rex Ultra 2 introduces intelligent checkpoint display and reminder alerts, enabling users to set key milestones, which helps better manage pacing and energy during long explorations, thereby enhancing efficiency and safety in extended adventures.
See More
- Significant Price Surge: Valaris shares jumped 21.8% to $76.02 on Monday, reflecting strong market confidence in the company's upcoming acquisition by Transocean, indicating a positive investor sentiment towards the deal.
- Clear Transaction Terms: Under the terms of the all-stock transaction, Valaris shareholders will receive 15.235 shares of Transocean stock for each Valaris share, which may attract more investor interest in Valaris's future performance.
- Mixed Market Performance: U.S. stocks were mixed on Monday, with the Nasdaq gaining around 100 points, showcasing strong performance in tech stocks amidst volatility in other sectors, reflecting the complexity of market sentiment.
- Investor Focus: The acquisition news surrounding Valaris has sparked widespread market attention, potentially influencing the stock prices of other related companies, prompting investors to closely monitor subsequent market reactions and industry developments.
See More









